Immunotherapy
Peanut SLIT-Tablet for Peanut Allergy
This trial tests a tablet containing small amounts of peanut protein taken under the tongue. It aims to help people with peanut allergies become less sensitive to peanuts. Participants will take gradually increasing doses to see if their tolerance improves.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Remibrutinib for Peanut Allergy
This trial is testing a treatment to see if it can help adults with peanut allergies tolerate peanuts better. People involved in the study will take the treatment for a short period and then try eating increasing amounts of peanut protein to see if their allergic reactions are reduced. The goal is to find out if the treatment can make it safer for people with peanut allergies to eat peanuts.
Popular Filters
Trials for Food Allergy Patients
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Biologics for Food Allergies
This trial tests omalizumab and dupilumab with oral immunotherapy in people aged 4 to 55 who have multiple food allergies, including peanut. The treatments aim to reduce allergic reactions and help the body build tolerance to allergens. Omalizumab has shown potential in speeding up the process and making it safer.
Frequently Asked Questions
Introduction to peanut allergy
What are the top hospitals conducting peanut allergy research?
In the realm of clinical trials aimed at finding solutions for peanut allergies, several hospitals are making significant strides. Western Sky Medical Research in El Paso is leading the charge with two ongoing trials and a total of nine completed studies dedicated to understanding and treating this condition since its first recorded trial in 2015. Meanwhile, Massachusetts General Hospital in Boston joins the ranks with two active peanut allergy trials and an impressive history of 16 completed studies dating back to their initial investigation in 2012. Boston Children's Hospital, also located in Boston, contributes to this important research with one ongoing trial and eight past investigations focused on peanut allergies since their debut study in 2014.
Across the country, MOORE-PH Dermatology - Clinical Research based in Tampa has emerged as a vital player by conducting one current clinical trial specifically targeting peanut allergies. Although they have only recently begun exploring treatments for this condition from their inaugural study launched just last year (2022), their commitment signifies promising developments on the horizon. Similarly, the newly established Boston Food allergy Center is dedicating its resources towards tackling peanut allergies head-on through one active trial that commenced alongside MOORE-PH Dermatology's efforts also during 2022.
These hospitals' endeavors shed light on how medical professionals are actively striving to find answers for those affected by peanut allergies—a growing concern worldwide. With each study conducted at these esteemed institutions, we move closer to breakthroughs that could potentially transform lives and provide hope for individuals currently grappling with this challenging allergenic response.
Which are the best cities for peanut allergy clinical trials?
When it comes to peanut allergy clinical trials, Boston in Massachusetts emerges as the leading city with four active studies focusing on Peanut SLIT-tablet, antibiotic/MTT, and Peanut oral immunotherapy. Following closely behind are Tampa in Florida, Normal in Illinois, El Paso in Texas, and Columbus in Ohio, each hosting two ongoing trials exploring treatments like Peanut SLIT-tablet and CNP-201. These cities provide individuals with peanut allergies access to cutting-edge research opportunities that hold promise for improving their quality of life and managing this potentially severe condition.
Which are the top treatments for peanut allergy being explored in clinical trials?
Exciting developments are underway in the search for effective treatments for peanut allergy. One noteworthy contender is the Peanut SLIT-tablet, currently being explored in one active clinical trial. Another promising option is CNP-201, which has shown potential and is also undergoing a single active trial. Equally notable is ligelizumab, advancing through its own solitary clinical trial. Lastly, Peanut oral immunotherapy has been gaining attention since its introduction in 2008 and continues to be investigated with one ongoing trial. With these innovative approaches on the horizon, there is renewed hope for individuals living with peanut allergies.
What are the most recent clinical trials for peanut allergy?
Recent clinical trials have brought hope to those suffering from peanut allergies, with the aim of finding effective treatments for this condition. One such trial is investigating the potential benefits of an antibiotic combined with MTT (microbial transfer therapy) in treating peanut allergy. Another study focuses on a Peanut SLIT-tablet, exploring its safety and efficacy as a possible treatment option for individuals with peanut allergies. CNP-201 has also shown promise in early-phase trials, demonstrating its potential effectiveness against peanut allergy. Additionally, ligelizumab is being evaluated in Phase 3 trials to assess its ability to provide relief from symptoms associated with peanut allergy. Lastly, a Phase 2 trial investigates the use of oral immunotherapy using peanuts as a method for desensitization among individuals affected by this allergen. These ongoing studies hold great potential for improving the lives of those living with peanut allergies.
What peanut allergy clinical trials were recently completed?
Recent clinical trials have made strides in addressing peanut allergy, an increasingly prevalent concern. In December 2021, Johns Hopkins University successfully completed a trial investigating the potential of Acalabrutinib as a treatment option for this condition. Additionally, the University of North carolina at Chapel Hill concluded their Peanut OIT trial in January 2018. These studies contribute to our understanding and potentially offer new approaches to managing peanut allergies, offering hope for those affected by this challenging condition.